Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis.
Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis.
复制标题
DOI:
10.3390/molecules26010157
复制
发表时间:
2020-12-31
期刊:
影响因子:
--
通讯作者:
King MR
中科院分区:
文献类型:
--
作者:
Zhang Z;Patel SB;King MR
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces cancer cell-specific apoptosis and has garnered intense interest as a promising agent for cancer treatment. However, the development of TRAIL has been hampered in part because most human cancer cells are resistant to TRAIL. A few small molecules including natural compounds such as piperlongumine (PL) have been reported to sensitize cancer cells to TRAIL. We prepared a novel type of nanomaterial, micelle-in-liposomes (MILs) for solubilization and delivery of PL. PL-loaded MILs were used to sensitize cancer cells to TRAIL. As visualized by cryo-TEM, micelles were successfully loaded inside the aqueous core of liposomes. The MILs increased the water solubility of PL by ~20 fold. A sustained PL release from MILs in physiologically relevant buffer over 7 days was achieved, indicating that the liposomes prevented premature drug release from the micelles in the MILs. Also demonstrated is a potent synergistic apoptotic effect in cancer cells by PL MILs in conjunction with liposomal TRAIL. MILs provide a new formulation and delivery vehicle for hydrophobic anticancer agents, which can be used alone or in combination with TRAIL to promote cancer cell death.
登录
查看更多内容
影响因子:
4.7
作者:
通讯作者:
--
影响因子:
3.7
作者:
Oerlemans C;Bult W;Bos M;Storm G;Nijsen JF;Hennink WE
通讯作者:
Hennink WE
影响因子:
5.5
作者:
Lu J;Owen SC;Shoichet MS
通讯作者:
Shoichet MS
DOI:
10.1081/bio-120028669
发表时间:
2004-01-01
期刊:
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY
影响因子:
--
作者:
Chaize, B;Colletier, JP;Fournier, D
通讯作者:
Fournier, D
影响因子:
3.8
作者:
Ortiz-Otero, Nerymar;Marshall, Jocelyn R.;King, Michael R.
通讯作者:
King, Michael R.